As the 2^nd Retinal Imaging Biomarkers & Endpoints Summit returned to Boston this summer, 80+ ophthalmic R&D scientists, imaging technology experts and algorithm engineers joined to discuss how they can harness the potential and implement novel retinal imaging tools for faster disease diagnosis and patient detection, streamlined clinical trials with accurate data readouts and non-invasive therapeutic interventions to improve patient’s quality of life.

24+ expert speakers from the likes of AbbVie, Alexion Pharmaceuticals, Astellas, Boehringer Ingelheim, Genentech, Novartis and Regeneron were present for the only industry-dedicated event focusing on streamlining imaging data analysis with the implementation of AI-based predictive measures for earlier detection and diagnosis to optimize patient stratification, selection and recruitment for trials.